Elekta AB stock (SE0000163628): earnings update keeps focus on growth and margins

Elekta AB has recently reported financial results and updated its outlook, keeping investors’ attention on margins, order intake and cash flow while the share trades on Nasdaq Stockholm amid ongoing healthcare tech demand.

Elekta AB, the Swedish maker of radiation therapy and oncology solutions, has remained in focus after publishing its latest quarterly results and updating investors on order trends and profitability targets, according to the company’s report released in late March 2026 and related materials from Nasdaq Stockholm. These announcements keep attention on margins, cash flow and capital allocation as the stock continues to trade on the Swedish market.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology / radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Hospitals and cancer centers in Europe, North America and emerging markets
• Key revenue drivers: Linear accelerators, software and related oncology services
• Home exchange/listing venue: Nasdaq Stockholm (ticker: EKTA B)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB focuses on devices and software used in radiation-based cancer treatment. The group develops linear accelerators, brachytherapy systems and oncology information platforms that help hospitals and cancer centers plan, deliver and monitor radiation therapy. This positions the company as a specialized supplier within global oncology care.

The business model combines capital equipment sales with recurring service and software revenues. Hospitals typically make large, infrequent purchases of radiation machines, followed by multi?year service contracts and upgrades. This mix creates an installed base that can generate recurring revenue streams through maintenance, training and digital tools, smoothing cash flows over time.

Elekta mainly addresses public and private healthcare providers that invest in long?lived treatment infrastructure. Purchasing cycles can be influenced by government funding, reimbursement frameworks and hospital budgeting. As a result, Elekta’s order intake and backlog development are closely tracked by investors as leading indicators for future revenue and margin dynamics.

The company also invests in research and development to keep its clinical offerings competitive. Advances in precision, imaging integration and workflow efficiency can support pricing power and differentiation versus other radiation oncology providers. R&D spending is therefore an important operating decision for management as it seeks to balance innovation with profitability.

Main revenue and product drivers for Elekta AB

Elekta’s core revenue driver is the sale of radiation therapy systems, often referred to as linacs, that are installed in dedicated treatment rooms. These systems form the backbone of many radiotherapy departments, and each installation typically involves project planning, shielding, commissioning and clinical ramp?up. The capital nature of these projects means that order timing can materially affect quarterly revenue recognition and reported growth rates.

In addition to hardware, Elekta generates income from treatment planning and oncology information software that helps clinicians design radiation doses and manage patient workflows. Software licenses, subscriptions and support contracts can provide higher margin recurring revenues compared with pure equipment sales, making software expansion a strategic priority for the company.

Service contracts tied to the installed base add another stream of recurring cash flows. Hospitals often rely on original equipment manufacturers for preventative maintenance, spare parts and system upgrades. For Elekta, the renewal rate and scope of such contracts can influence long?term gross margins. A growing installed base may support more predictable revenue even in years with softer capital spending.

Geographically, Elekta serves a broad set of regions, including Western Europe, North America and selected emerging markets. Demand in mature markets is often driven by replacement of older systems and the introduction of more advanced treatment techniques, while emerging markets may focus on expanding basic radiotherapy capacity. Currency movements between the Swedish krona, the US dollar and the euro can therefore impact reported revenue and profitability.

Industry trends and competitive position

The market for radiation oncology equipment is influenced by long?term cancer incidence trends and healthcare infrastructure investment. As populations age and diagnostic standards improve, demand for radiotherapy capacity tends to grow. This underpins structural demand for Elekta’s systems and services over multi?year horizons, even though annual order patterns can fluctuate with budget cycles and macroeconomic conditions.

Elekta competes with other large medical technology groups that also offer radiation oncology and imaging solutions. Competitive dynamics can affect pricing, service terms and technology roadmaps. Management’s ability to differentiate through clinical performance, workflow integration and total cost of ownership is therefore a central consideration for investors assessing the company’s long?term prospects in this specialized niche.

Beyond pure equipment competition, regulatory requirements, product approvals and quality management are important. Medtech companies must comply with strict safety and performance standards, and any delays in approvals or manufacturing issues can impact deliveries. For Elekta, maintaining robust quality systems and regulatory relationships is an ongoing operational priority with direct financial relevance.

Why Elekta AB matters for US investors

For US investors, Elekta AB represents exposure to the global radiotherapy and oncology equipment market from a European perspective. While the shares are listed on Nasdaq Stockholm in Swedish krona, a notable portion of the company’s revenue is generated in North America and other international markets, linking its performance to trends in US healthcare spending and oncology treatment volumes.

US?based institutional and retail investors who follow the medical technology sector often track developments at overseas peers to gauge technological progress, pricing dynamics and hospital purchasing behavior. Elekta’s updates on order intake, backlog and profitability may therefore be considered alongside results from US?listed medtech companies that also participate in oncology, imaging and surgery markets.

Currency considerations can play a role for US investors analyzing Elekta. Movements between the US dollar and the Swedish krona can influence reported results and any potential valuation comparisons with US?listed peers. In addition, differences in accounting frameworks, regulatory environments and dividend practices between Sweden and the US may be relevant when assessing the stock’s risk and return characteristics.

Conclusion

Elekta AB remains positioned as a focused player in radiation oncology, combining capital equipment with recurring software and service revenues. Recent financial updates have kept investor attention on order intake, margins and cash flow as hospitals manage budgets and investment plans. For US and international investors following healthcare technology, the company provides a window into global radiotherapy demand and competitive dynamics, but also involves exposure to currency movements, regulatory frameworks and capital spending cycles that can affect earnings volatility over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.